Amneal Pharmaceuticals (AMRX) Misses Q4 EPS by 2c

Amneal Pharmaceuticals (NASDAQ: AMRX) reported Q4 EPS of $0.18, $0.02 worse than the analyst estimate of $0.20. Revenue for the quarter came in at $537 million versus the consensus estimate of $537.35 million.

GUIDANCE:

Amneal Pharmaceuticals sees FY2022 revenue of $2.15-2.25 billion, versus the consensus of $2.17 billion. The company also guides $540 to $560 million in adjusted EBITDA.

For earnings history and earnings-related data on Amneal Pharmaceuticals (AMRX) click here.

You May Also Be Interested In

• Is the global equity rally broadening? UBS weighs in
• Faraday Future signs robotics distributor deal, plans partner event
• Deere & Co. (DE) Tops Q3 EPS by 41c, raises guidance